Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.49 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989888 | 1.00 | SLC6A3 (0.58) | SLC6A3SLC6A2CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL747151 | 0.84 | CYP2D6 (0.44) | SLC6A3SLC6A2CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL747150 | 0.84 | CYP2D6 (0.44) | SLC6A3SLC6A2CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL6511353 | 0.81 | SLC6A3 (0.70) | SLC6A3SLC6A2OPRK1DRD3 | |
| SCHEMBL1177399 | 0.81 | SLC6A3 (0.70) | SLC6A3SLC6A2OPRK1DRD3 | |
| SCHEMBL1177400 | 0.81 | SLC6A3 (0.70) | SLC6A3SLC6A2OPRK1DRD3 | |
| SCHEMBL15918739 | 0.80 | CHRNA3 (0.51) | CHRNB2CHRNA4CHRNA3CHRNB1CHRNB4 | |
| SCHEMBL15780659 | 0.80 | CHRNA3 (0.54) | CHRNB2CHRNA4CHRNA3CHRNB1CHRNB4 | |
| SCHEMBL989954 | 0.78 | SLC6A2 (0.50) | SLC6A3SLC6A2OPRK1CHRM4 | |
| SCHEMBL1547720 | 0.77 | CHRNA3 (0.49) | CHRNB2CHRNA4CHRNA3CHRNB1CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431368-B1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBVIE BAHAMAS LTD (BS) | 2014-08-27 | — | — | EP | disclosed |
| EP-2431368-A1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | Abbott Laboratories (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2018380-B1 | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7872017-B2 | Fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | MALT1, BMP2, ALKBH2 | SLC6A3 2587/4885SLC6A2 2602/4885CHRNB2 2585/4885 |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | MALT1, BMP2, ALKBH2 | SLC6A3 2587/4885SLC6A2 2602/4885CHRNB2 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.